Mitogen-Activated Protein Kinase Pathway: Genetic Analysis of 95 Adrenocortical Tumors

REFERENCES

• Shirodkar M, Jabbour SA. Endocrine incidentalomas. Int J Clin Pract 2008;62:1423–1431. doi: 10.1111/j.17421241.2008.01831.x
   PubMed Web of Science ®Google Scholar
• Tissier F. Classification of adrenal cortical tumors: what limits for the pathological approach? Best Pract Res Clin Endocrinol Metab 2010;24:877–885. doi: 10.1016/j.beem.2010.10.011
   PubMed Web of Science ®Google Scholar
• Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM,Adrenocortical carcinoma. Endocr Rev 2014;35:282–326. doi: 10.1210/er.2013-1029
   PubMed Web of Science ®Google Scholar
• Fassnacht M, Libé R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician's update. Nat Rev Endocrinol 2011;7:323–335. doi: 10.1038/nrendo.2010.235
   PubMed Web of Science ®Google Scholar
• Bertherat J, Bertagna X. Pathogenesis of adrenocortical cancer. Best Pract Res Clin Endocrinol Metab 2009;23:261–271. doi: 10.1016/j.beem.2008.10.006
   PubMed Web of Science ®Google Scholar
• Lehmann T, Wrzesinski T. The molecular basis of adrenocortical cancer. Cancer Genet 2012;205:131–137. doi: 10.1016/j.cancergen.2012.02.009
   PubMed Web of Science ®Google Scholar
• Bussey KJ, Demeure MJ. Toward a pathway-centered approach for the treatment of adrenocortical carcinoma. Curr Opin Oncol 2011;23:34–44. doi: 10.1097/CCO.0b013e328340d879
   PubMed Web of Science ®Google Scholar
• Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011;11:761–774. doi: 10.1038/nrc3106
   PubMed Web of Science ®Google Scholar
• Takashima A, Faller DV. Targeting the RAS oncogene. Expert Opin Ther Targets 2013;17:507–531. doi: 10.1517/14728222.2013.764990
   PubMed Web of Science ®Google Scholar
• Yashiro T, Hara H, Fulton NC,Obara T, Kaplan EL. Point mutations of ras genes in human adrenal cortical tumors: absence in adrenocortical hyperplasia. World J Surg 1994;18:455–460; discussion 460–461.
   PubMed Web of Science ®Google Scholar
• Moul JW, Bishoff JT, Theune SM, Chang EH. Absent ras gene mutations in human adrenal cortical neoplasms and pheochromocytomas. J Urol 1993;149:1389–1394.
   PubMed Web of Science ®Google Scholar
• Rahman MA, Salajegheh A, Smith RA, Lam AK-Y. B-Raf mutation: a key player in molecular biology of cancer. Exp Mol Pathol 2013;95:336–342. doi: 10.1016/j.yexmp.2013.10.005
   PubMed Web of Science ®Google Scholar
• Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2–16. doi: 10.1016/j.gene.2005.10.018
   PubMed Web of Science ®Google Scholar
• Kotoula V, Sozopoulos E, Litsiou H, Fanourakis G, Koletsa T, Voutsinas G, Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. Endocr Relat Cancer 2009;16:565–572. doi: 10.1677/ERC-08-0101
   PubMed Web of Science ®Google Scholar
• Aubert S, Wacrenier A, Leroy X, Devos P, Carnaille B, Proye C, Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol 2002;26:1612–1619.
   PubMed Web of Science ®Google Scholar
• Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 2009;115:243–250. doi: 10.1002/cncr.24030
   PubMed Web of Science ®Google Scholar
• Pezzani R, Rubin B, Redaelli M, Radu C, Barollo S, Cicala MV, The antiproliferative effects of ouabain and everolimus on adrenocortical tumor cells. Endocr J 2014;61: 41–53.
   PubMed Web of Science ®Google Scholar
• Barollo S, Pezzani R, Cristiani A, Redaelli M, Zambonin L, Rubin B, Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations. Thyroid Off J Am Thyroid Assoc 2014;24:809–819. doi: 10.1089/thy.2013.0403
   PubMed Web of Science ®Google Scholar
• Sadow PM, Heinrich MC, Corless CL, Fletcher JA, Nosé V.Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas. Endocr Pathol 2010;21:73–79. doi: 10.1007/s12022-009-9101-3
   PubMed Web of Science ®Google Scholar
• Adam P, Hahner S, Hartmann M, Heinrich B, Quinkler M, Willenberg HS, Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. Mod Pathol Off J U S Can Acad Pathol Inc 2010;23:1596–1604. doi: 10.1038/modpathol.2010.153
   PubMed Web of Science ®Google Scholar
• Mariniello B, Rosato A, Zuccolotto G, Rubin B, Cicala MV, Finco I, Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models. Endocr Relat Cancer 2012;19:527–539. doi: 10.1530/ERC-11-0337
   PubMed Web of Science ®Google Scholar
• Redaelli M, Franceschi V, Capocefalo A, D'Avella D, Denaro L, Cavirani S, Herpes simplex virus type 1 thymidine kinase-armed bovine herpesvirus type 4-based vector displays enhanced oncolytic properties in immunocompetent orthotopic syngenic mouse and rat glioma models. Neuro-Oncol 2012;14:288–301. doi: 10.1093/neuonc/nor219
   PubMed Web of Science ®Google Scholar
• Ocker M, Sachse R, Rico A, Hensen J. PCR-SSCP analysis of human adrenocortical adenomas: absence of K-ras gene mutations. Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc 2000;108:513–514. doi: 10.1055/s-2000-11006
   PubMed Web of Science ®Google Scholar
• Masi G, Lavezzo E, Iacobone M, Favia G, Palù G, Barzon L.Investigation of BRAF and CTNNB1 activating mutations in adrenocortical tumors. J Endocrinol Invest 2009;32:597–600. doi: 10.3275/6294
   PubMed Web of Science ®Google Scholar
• Herbet M, Salomon A, Feige J-J, Thomas M. Acquisition order of ras and p53 gene alterations defines distinct adrenocortical tumor phenotypes. PLoS Genet 2012;8:e1002700. doi: 10.1371/journal.pgen.1002700
   Google Scholar
• Cantwell-Dorris ER, O'Leary JJ, Sheils OM. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther 2011;10:385–394. doi: 10.1158/1535-7163.MCT-10-0799
   PubMed Web of Science ®Google Scholar
• Pennelli G, Vianello F, Barollo S, Pezzani R, Merante Boschin I, Pelizzo MR, BRAF(K601E) mutation in a patient with a follicular thyroid carcinoma. Thyroid Off J Am Thyroid Assoc 2011;21:1393–1396. doi: 10.1089/thy.2011.0120
   PubMed Web of Science ®Google Scholar
• Dent P. Crosstalk between ERK, AKT, and cell survival. Cancer Biol Ther 2014;15:245–246. doi: 10.4161/cbt.27541
   PubMedGoogle Scholar